Actively Recruiting
Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose
Led by Jane Yardley · Updated on 2026-03-12
30
Participants Needed
1
Research Sites
80 weeks
Total Duration
On this page
Sponsors
J
Jane Yardley
Lead Sponsor
D
Diabetes Québec
Collaborating Sponsor
AI-Summary
What this Trial Is About
People living with type 1 diabetes (PwT1D) are recommended to administer insulin 10-15 minutes before meal consumption (pre-bolus), to account for the delay in the glucose lowering action associated with subcutaneously administered insulin. Due to the demands of day-to-day life, pre-bolusing is not always possible or may be forgotten. With continuous glucose monitors (CGMs), PwT1D may be alerted to this missed insulin dose by a CGM alert, including rapidly rising glucose (change \>2.5mmol/L/15min) or hyperglycemia (\>10.0 mmol/L), and deliver a mistimed (post-prandial) dose in response to CGM alert. This study was designed to determine the effect of combining a post-prandial/mistimed insulin dose with 15 minutes of brisk walking. It is expected that walking will help to minimize or prevent hyperglycemia after a mistimed bolus insulin dose, as well as blunt the rise in glucose following a mistimed insulin dose.
CONDITIONS
Official Title
Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 24 years
- Diagnosed with type 1 diabetes for at least two years
- Estimated glycated hemoglobin or glucose management indicator below 9.9% from the last 30 days of CGM data
- Routine use of a Dexcom G7 continuous glucose monitor
You will not qualify if you...
- Changes in insulin treatment strategy within the past 2 months
- Diagnosis of gastroparesis
- Conditions that make exercise harmful
- Intolerance to gluten or lactose
- Significant kidney disease (eGFR below 30 ml/min)
- Unable to provide informed consent due to cognitive issues
- Taking medications other than insulin that affect glucose metabolism, unless stable for over three months
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada, H2W 1R7
Actively Recruiting
Research Team
C
Corinne Suppère, MSc
CONTACT
J
Jane Yardley, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here